New Delhi: Pharma major  Cipla Limited today sought the permission of the Drugs Controller General of India’s (DCGI) for importing and marketing authorisation of Moderna’s Covid-19 vaccine. As per official sources, the DCGI may soon grant restricted emergency use authorisation for Moderna’s COVID-19 vaccine.

Cipla, on behalf of the US pharma major, has requested for import and marketing authorisation of these jabs. According to the sources, approval is likely to come anytime as the CDSCO is in favour of doing so.

Cipla filed an application on Monday seeking permission for import of Moderna COVID-19 vaccine referring to DCGI notices dated April 15 and June 1 stating that if the vaccine is approved by the USFDA for EUA, the vaccine can be granted marketing authorization without bridging trial and assessment of safety data of first 100 beneficiaries of vaccines shall be submitted before rolling out in immunization programme

Moderna has also informed that the US Government has agreed to donate a certain number of doses of the Moderna COVID-19 vaccine through COVAX to the Government of India for use and has sought approval from the Central Drugs Standard Control Organisation  for these vaccines.

Not only Delta Plus but these three variants also very dangerous, can be big threat to the whole world

UP CM issues new set of guideless for dealing with patients infected with Delta Plus

Vaccination of 16 people on the same Aadhaar number in no 1 vaccinator state MP!